StevenMBairMD

PubMed

• Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.
  Davila, E., Bradeen, X., Abbott, D., Zain, J., Kamdar, M., Neuwelt, A., Jasem, J., Porcu, P., Major, A., Major, A., Haverkos, B., Major, A., Bair, S., Smith, C.> ;Blood Advances. 2024 Feb 13
• Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
  Jackson T Bowers, Jacob Anna, Steven M Bair, Kaitlin Annunzio, Narendranath Epperla, Jerrin Joy Pullukkara, Sameh Gaballa, Michael A Spinner, Shuning Li, Marcus R Mess...> ;Blood Advances. 2023 Nov 14
• 17 citations
  Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
  Nicole A. Carreau, Philippe Armand, Reid W. Merryman, Ranjana H. Advani, Michael A. Spinner, Alex F. Herrera, Radhakrishnan Ramchandren, Muhammad Saad Hamid, Sarit Ass...> ;British Journal of Haematology. 2020 Oct 1
• 24 citations
  Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy.
  Nicole A. Carreau, Orrin Pail, Philippe Armand, Reid W. Merryman, Ranjana H. Advani, Michael A. Spinner, Alex F. Herrera, Robert T. Chen, Sarah Tomassetti, Radhakrishn...> ;The Oncologist. 2020 Oct 1
• 6 citations
  Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma
  Reid W. Merryman, Nicole A. Carreau, Ranjana H. Advani, Michael A. Spinner, Alex F. Herrera, Robert T. Chen, Sarah Tomassetti, Radhakrishnan Ramchandren, Muhammad Hami...> ;The Oncologist. 2020 Jun 1
• 29 citations
  Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
  Jakub Svoboda, Steven M. Bair, Daniel J. Landsburg, Sunita D. Nasta, Sarah J. Nagle, Stefan K. Barta, Nadia Khan, Joanne Filicko-O'Hara, Sameh Gaballa, Lauren E. Strel...> ;Haematologica. 2020 May 15
• 15 citations
  Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy.
  Steven M. Bair, Joshua D Brandstadter, Emily C. Ayers, Edward A. Stadtmauer> ;Cancer. 2020 May 1
• 23 citations
  Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
  Steven M. Bair, Lauren E. Strelec, Tatyana Feldman, Gulrayz Ahmed, Philippe Armand, Nirav N. Shah, Arun N. Singavi, Nishitha Reddy, Nadia Khan, Charalambos Andreadis, ...> ;The Oncologist. 2019 Jul 1
• 16 citations
  Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor T-cell therapy for chronic ...
  Steven M. Bair, David L. Porter> ;American Journal of Hematology. 2019 May 1
• 1 citations
  Response-Adapted Treatment Strategies in Hodgkin Lymphoma Using PET Imaging.
  Steven M. Bair, Jakub Svoboda> ;PET Clinics. 2019 Apr 12
• 11 citations
  Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
  Steven M. Bair, Anthony R. Mato, Jakub Svoboda> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Jun 1
• 28 citations
  Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospect...
  Steven M. Bair, Lauren E. Strelec, Sarah J. Nagle, Sunita D. Nasta, Daniel J. Landsburg, Anthony R. Mato, Alison W. Loren, Stephen J. Schuster, Edward A. Stadtmauer, J...> ;American Journal of Hematology. 2017 Sep 1
• 439 citations
  NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
  Jonathan D. Brown, Charles Y. Lin, Qiong Duan, Gabriel K. Griffin, Alexander J. Federation, Ronald M. Paranal, Steven M. Bair, Gail Newton, Andrew H. Lichtman, Andrew ...> ;Molecular Cell. 2014 Oct 23
• 112 citations
  SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer
  Lianjie Li, Chuan Shen, Eijiro Nakamura, Kiyohiro Ando, Sabina Signoretti, Rameen Beroukhim, Glenn S. Cowley, Patrick H. Lizotte, Ella Liberzon, Steven M. Bair, David ...> ;Cancer Cell. 2013 Dec 9
• 80 citations
  Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives
  Steven M. Bair, Toni K. Choueiri, Javid Moslehi> ;Trends in Cardiovascular Medicine. 2013 May 1
• 9 citations
  No telomere shortening in marrow stroma from patients with MDS.
  A. Mario Marcondes, Steven M. Bair, Peter S. Rabinovitch, Ted Gooley, H. Joachim Deeg, Rosana Risques> ;Annals of Hematology. 2009 Jul 1
• 15 citations
  Transplantation of allogeneic T cells alters iron homeostasis in NOD/SCID mice
  Steven M. Bair, Emily Spaulding, Jaakko Parkkinen, Howard M. Shulman, Vladimir Lesnikov, Mary Beauchamp, François Canonne-Hergaux, Kris V. Kowdley, H. Joachim Deeg> ;Blood. 2009 Feb 19
• Join now to see all

Abstracts/Posters

• Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Mu...
  Steven M. Bair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas
  Steven M. Bair, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018